Russia Insulin Drugs and Delivery Devices Market Size (2024 - 2029)

The Russia Insulin Drugs and Delivery Devices Market is projected to experience growth over the forecast period, driven by an increasing prevalence of diabetes and heightened healthcare expenditures. The COVID-19 pandemic has underscored the importance of diabetic care, as diabetes is linked to poorer outcomes in COVID-19 patients. Efforts to enhance diabetes prevention and control, such as improving insulin access and regulatory harmonization, are expected to contribute to the market's expansion.

Home Market Analysis Healthcare Research Device Drug Combination Research Diagnostics and Therapeutics Research Diabetes Care Research Russia Insulin Drugs & Delivery Devices Market Market Size

Market Size of Russia Insulin Drugs and Delivery Devices Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
RussiaDD
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Market Size (2024) USD 1.10 Billion
Market Size (2029) USD 1.14 Billion
CAGR (2024 - 2029) 0.58 %

Major Players

Russia Insulin Drugs and Delivery Devices Market Major Players

*Disclaimer: Major Players sorted in no particular order

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Russia Insulin Drugs & Delivery Devices Market Analysis

The Russia Insulin Drugs and Delivery Devices Market size is estimated at USD 1.10 billion in 2024, and is expected to reach USD 1.14 billion by 2029, growing at a CAGR of 0.58% during the forecast period (2024-2029).

The COVID-19 pandemic has resulted in premature deaths, particularly among the elderly, in its first year of existence. Russia has the ninth-highest number of confirmed COVID-19 cases in the world. The majority of COVID-19 deaths were caused by the co-occurrence of two or more chronic conditions in the same person. Several studies have found that chronic diseases such as diabetes are linked to poor outcomes in COVID-19 patients.

Diabetic drugs are medications designed to stabilise and control blood glucose levels in diabetics. Diabetic drugs have been proposed as potential treatments for diabetic patients infected with SARS-CoV-2 during the COVID-19 pandemic. The rapidly increasing incidence and prevalence of diabetic patients, as well as healthcare expenditure, indicate that diabetic care products are being used more frequently. According to Roscongress, Russia ranks fifth in the world in terms of the number of people aged 20 to 79 who have diabetes mellitus. Furthermore, during COVID-19, the mortality rate among diabetic patients increased by 22%.

The World Health Assembly agreed on a Resolution to strengthen diabetes prevention and control in May 2021. It suggests actions such as increasing insulin access, promoting convergence and harmonisation of regulatory requirements for insulin and other diabetes medicines and health products, and assessing the feasibility and potential value of establishing a web-based tool to share information relevant to market transparency for diabetes medicines and health products.

As a result of the aforementioned factors, the studied market is expected to grow during the analysis period.

Russia Insulin Drugs & Delivery Devices Industry Segmentation

Russia Insulin Drugs and Delivery Devices Market is segmented into Drugs (Basal or Long-acting Insulins, Bolus or Fast-acting Insulins, Traditional Human Insulins, Combination Insulins, and Biosimilar Insulins), Devices (Insulin Pens, Insulin Pumps, Insulin Syringes, and Jet Injectors). The report offers the value (in USD million) and volume (in million mL) for insulin drugs and (in unit million) for the devices for the above segments.

Drug (Value and Volume, 2016 - 2027)
Basal or Long-acting Insulins
Lantus (Insulin Glargine)
Levemir (Insulin Detemir)
Toujeo (Insulin Glargine)
Tresiba (Insulin Degludec)
Basaglar (Insulin Glargine)
Bolus or Fast-acting Insulins
NovoRapid/Novolog (Insulin aspart)
Humalog (Insulin lispro)
Apidra (Insulin glulisine)
FIASP (Insulin aspart)
Admelog (Insulin lispro Sanofi)
Traditional Human Insulins
Novolin/Mixtard/Actrapid/Insulatard
Humulin
Insuman
Combination Insulins
NovoMix (Biphasic Insulin aspart)
Ryzodeg (Insulin degludec and Insulin aspart)
Xultophy (Insulin degludec and Liraglutide)
Soliqua/Suliqua (Insulin glargine and Lixisenatide)
Biosimilar Insulins
Insulin Glargine Biosimilars
Human Insulin Biosimilars
Device (Value and Volume, 2016 - 2027)
Insulin Pumps
Insulin Pump Devices
Insulin Pump Reservoirs
Insulin Infusion sets
Insulin Pens
Cartridges in reusable pens
Disposable insulin pens
Insulin Syringes
Insulin Jet Injectors
Need A Different Region Or Segment?
Customize Now

Russia Insulin Drugs and Delivery Devices Market Size Summary

The Russia Insulin Drugs and Delivery Devices Market is poised for growth, driven by an increasing prevalence of diabetes and the need for effective management solutions. The market is characterized by a shift towards advanced insulin delivery systems, such as insulin pumps, which offer continuous and more precise insulin administration compared to traditional methods. This transition is supported by technological advancements and a growing preference for devices that mimic natural insulin delivery, particularly for Type 1 diabetes patients. The market landscape is consolidated, with major players like Roche, Medtronics, Novo Nordisk, Eli Lilly, and Sanofi actively engaging in partnerships and collaborations to enhance their market presence and develop innovative solutions. Initiatives such as the Cities Changing Diabetes program in Moscow highlight the ongoing efforts to address diabetes challenges and improve care delivery.

The market's expansion is further bolstered by government initiatives and healthcare policies aimed at improving diabetes care and reducing out-of-pocket expenses for patients. The Russian government's focus on implementing a National Diabetes Plan and enhancing the reimbursement system underscores the commitment to tackling the diabetes epidemic. Additionally, the introduction of new products and increased public awareness present significant opportunities for market participants. The collaboration between companies like CamDiab and Ypsomed to develop integrated automated insulin delivery systems exemplifies the industry's drive towards smarter, data-driven solutions for diabetes management. As the market evolves, the emphasis on early detection, prevention, and comprehensive care continues to shape the future of diabetes management in Russia.

Explore More

Russia Insulin Drugs and Delivery Devices Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

    3. 1.3 Market Restraints

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Bargaining Power of Suppliers

      2. 1.4.2 Bargaining Power of Consumers

      3. 1.4.3 Threat of New Entrants

      4. 1.4.4 Threat of Substitute Products and Services

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 Drug (Value and Volume, 2016 - 2027)

      1. 2.1.1 Basal or Long-acting Insulins

        1. 2.1.1.1 Lantus (Insulin Glargine)

        2. 2.1.1.2 Levemir (Insulin Detemir)

        3. 2.1.1.3 Toujeo (Insulin Glargine)

        4. 2.1.1.4 Tresiba (Insulin Degludec)

        5. 2.1.1.5 Basaglar (Insulin Glargine)

      2. 2.1.2 Bolus or Fast-acting Insulins

        1. 2.1.2.1 NovoRapid/Novolog (Insulin aspart)

        2. 2.1.2.2 Humalog (Insulin lispro)

        3. 2.1.2.3 Apidra (Insulin glulisine)

        4. 2.1.2.4 FIASP (Insulin aspart)

        5. 2.1.2.5 Admelog (Insulin lispro Sanofi)

      3. 2.1.3 Traditional Human Insulins

        1. 2.1.3.1 Novolin/Mixtard/Actrapid/Insulatard

        2. 2.1.3.2 Humulin

        3. 2.1.3.3 Insuman

      4. 2.1.4 Combination Insulins

        1. 2.1.4.1 NovoMix (Biphasic Insulin aspart)

        2. 2.1.4.2 Ryzodeg (Insulin degludec and Insulin aspart)

        3. 2.1.4.3 Xultophy (Insulin degludec and Liraglutide)

        4. 2.1.4.4 Soliqua/Suliqua (Insulin glargine and Lixisenatide)

      5. 2.1.5 Biosimilar Insulins

        1. 2.1.5.1 Insulin Glargine Biosimilars

        2. 2.1.5.2 Human Insulin Biosimilars

    2. 2.2 Device (Value and Volume, 2016 - 2027)

      1. 2.2.1 Insulin Pumps

        1. 2.2.1.1 Insulin Pump Devices

        2. 2.2.1.2 Insulin Pump Reservoirs

        3. 2.2.1.3 Insulin Infusion sets

      2. 2.2.2 Insulin Pens

        1. 2.2.2.1 Cartridges in reusable pens

        2. 2.2.2.2 Disposable insulin pens

      3. 2.2.3 Insulin Syringes

      4. 2.2.4 Insulin Jet Injectors

Russia Insulin Drugs and Delivery Devices Market Size FAQs

The Russia Insulin Drugs and Delivery Devices Market size is expected to reach USD 1.10 billion in 2024 and grow at a CAGR of 0.58% to reach USD 1.14 billion by 2029.

In 2024, the Russia Insulin Drugs and Delivery Devices Market size is expected to reach USD 1.10 billion.

Russia Insulin Drugs & Delivery Devices Market Report Snapshots

Russia Insulin Drugs & Delivery Devices Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)